Feedback

Radionuclide Cisternography with [ 64 Cu]Cu-DOTA

ORCID
0000-0002-3779-6298
Affiliation
Working Group for Translational Nuclear Medicine and Radiopharmacy, Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany;
Greiser, Julia;
Affiliation
Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany(C.K.);
Groeber, Sebastian;
Affiliation
Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany(C.K.);
Weisheit, Thomas;
Affiliation
Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany(C.K.);
Niksch, Tobias;
Affiliation
Neurology, Jena University Hospital, 07747 Jena, Germany
Schwab, Matthias;
Affiliation
Neurosurgery, Jena University Hospital, 07747 Jena, Germany;
Senft, Christian;
ORCID
0000-0003-3307-1772
Affiliation
Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany(C.K.);
Kuehnel, Christian;
Affiliation
Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany(C.K.);
Drescher, Robert;
ORCID
0000-0002-6462-3851
Affiliation
Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany(C.K.);
Freesmeyer, Martin

Radionuclide cisternography (RNC) is a method for conducting imaging of the cerebrospinal system and can be used to identify cerebrospinal fluid leaks. So far, RNC has commonly employed radiopharmaceutical agents suitable only for single-photon emission tomography techniques, which are thus lacking in terms of image resolution and can potentially lead to false-negative results. Therefore, [ 64 Cu]Cu-DOTA was investigated as an alternative radiopharmaceutical for RNC, employing positron emission tomography (PET) instead of single-photon emission tomography. A formulation of [ 64 Cu]Cu-DOTA was produced according to the guidelines for good manufacturing practice. The product met the requirements of agents suitable for intrathecal application. [ 64 Cu]Cu-DOTA was administered to a patient and compared to the approved scintigraphic RNC agent, [ 111 In]In-DTPA. While no cerebrospinal fluid leak was detected with [ 111 In]In-DTPA, [ 64 Cu]Cu-DOTA RNC exhibited a posterolateral leak between the vertebral bodies C1 and C2. Thus, in this patient, PET RNC with [ 64 Cu]Cu-DOTA was superior to RNC with [ 111 In]In-DTPA. Since radiopharmaceuticals have a very good safety profile regarding the occurrence of adverse events, PET RNC with [ 64 Cu]Cu-DOTA may become an attractive alternative to scintigraphic methods, and also to computed tomography or magnetic resonance imaging, which often require contrast agents, causing adverse events to occur much more frequently.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © 2023 by the authors.

Use and reproduction: